Evotec SEEVO +1.11%63 Pretax Margin % is -78.00% as of Mar. 2026. GuruFocus rates EVO with a GF Score™ of 63/100 and a GF Value™ of $4.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Evotec SE ranks worse than 83.04% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Evotec SE's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-141.2 Mil. Evotec SE's Revenue for the
three
months ended in Mar. 2026 was $181.1 Mil. Therefore, Evotec SE's pretax margin for the quarter that ended in Mar. 2026 was -78.00%.
The historical rank and industry rank for Evotec SE's Pretax Margin % or its related term are showing as below:
EVO'
s Pretax Margin % Range Over the Past 10 Years
Min: -24.34 Med: 7.43 Max: 38.34
Current: -24.04
EVO's Pretax Margin % is ranked worse than 83.04% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs EVO: -24.04
Evotec SE (NAS:EVO) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Evotec SE Pretax Margin % Related Terms
Evotec SE Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Evotec SE's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVO vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Evotec SE's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (EVO) has a Pretax Margin % of -78.00% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #793 out of 955 companies in the Drug Manufacturers industry, placing it in the top 83%.
Is Evotec SE's Pretax Margin % too high?
Evotec SE's current Pretax Margin % is -78.00%. Based on the distribution chart, Evotec SE ranks #793 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #793 out of 955 companies for Pretax Margin %. This places Evotec SE in the lower half of its industry. The industry median Pretax Margin % is 7.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Pretax Margin % is -78.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.26, compared to a current price of $2.74 — trading 35.7% below its estimated fair value. The current Pretax Margin % is -78.00%. Evotec SE's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Evotec SE (EVO), the current Pretax Margin % is -78.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $2.74 is trading 35.7% below its estimated GF Value™ of $4.26.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
Pretax Margin %: -78.00%
GF Value™: $4.26 vs. price of $2.74 (35.7% below fair value)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
63GF Score
Get the complete analysis for EVO
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
